Research Article Volume 01, Issue No. 01. 2024

The Medical Journal of Clinical Nutrition and Family Medicine



Management of Iron Deficiency Anemia

[1] Wahyudi, [1] Ahmad

[1] Faculty of Medicine, Sebelas Maret University, Surakarta City, Central Java, Indonesia

Correspondence : dr.wahyudi93827617@gmail.com

Article History :

Received date : 2024/10/18
Revised date : 2024/11/25
Accepted date : 2024/12/17
Published date : 2025/01/08

Copyright: *© 2024 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (BY NC) license (https://creativecommons.org/licenses/by-nc/4.0/).*

ABSTRACT

Background: The management of iron deficiency anemia (IDA) has garnered significant attention in recent years, particularly in understanding its complex mechanisms and treatment modalities. **Literature Review:** The literature also highlights the broader implications of ID in specific populations. For instance, (Cristina Fernandez-Jimenez et al., 2020) emphasizes the non-hematological manifestations of ID in menstruating women, which can significantly affect their quality of life. Furthermore, (Resál et al., 2021) address the challenges of managing IDA in patients with inflammatory bowel disease (IBD), advocating for increased awareness and the preferential use of parenteral iron supplementation in these cases. The relationship between iron, inflammation, and gut microbiota is explored by (J. Malesza et al., 2022), who advocate for personalized dietary recommendations alongside iron supplementation to optimize treatment outcomes. The significance of IDA in pregnancy is highlighted by (K Raut & M Hiwale, 2022), who call for more research into the safety and efficacy of IV iron in this population, addressing the underutilization of effective treatment options. Innovative approaches to iron supplementation are presented by (Jiang et al., 2022), who introduce a new chelated iron supplement that may enhance absorption and adherence. Lastly, (Rieg et al., 2023) examine the impact of IV iron on gut microbiota, raising important questions about the long-term implications of iron therapy on gut health. **Conclusions:** In conclusion, the literature reflects a growing understanding of the multifaceted nature of IDA, emphasizing the importance of tailored treatment strategies that consider individual patient circumstances, underlying health conditions, and the potential implications of different iron supplementation methods. Continued research is essential to refine these approaches and enhance patient outcomes in the management of iron deficiency anemia.

Keywords: Management, Iron Deficiency Anemia

Downloaded from The Medical Journal of Clinical Nutrition and Family Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

INTRODUCTION

The management of iron deficiency anemia (IDA) has garnered significant attention in recent years, particularly in understanding its complex mechanisms and treatment modalities. The literature review begins with the work of (FAHAD K ALSHARARI et al., 2017), which provides a comprehensive overview of the diagnostic and treatment strategies for IDA in adults. This article highlights the multifaceted nature of iron deficiency, emphasizing the importance of understanding hepcidin's role in iron metabolism regulation and the development of diagnostic tools like the soluble transferrin receptor to ferritin ratio. The authors advocate for aetiological treatment approaches, including both oral and parenteral iron supplementation, while also addressing the significance of morphological examinations in identifying underlying causes.

In the same year, (Tomkins et al., 2017) explore the implications of gastrointestinal (GI) diseases on iron deficiency and IDA. Their findings indicate that patients with GI-related IDA face higher rates of hospital re-attendance and increased mortality. They suggest that intravenous (IV) iron supplementation may offer a more effective and better-tolerated alternative to oral iron, particularly for patients with compromised intestinal absorption due to their GI conditions.

(Bhandari et al., 2018) further the discussion by examining the evolution of IV iron therapies. They note that while oral iron remains a common treatment, its gastrointestinal side effects limit its efficacy. The authors stress the necessity of addressing the underlying causes of IDA, particularly in patients with chronic conditions, and highlight the critical role of correcting perioperative IDA to improve patient outcomes.

The focus shifts in 2020 with the research by (Cristina Fernandez-Jimenez et al., 2020), who investigate the broader implications of iron deficiency in menstruating adult women. They emphasize that ID is not merely a hematological concern but has significant non-hematological manifestations, such as fatigue and cognitive impairments. Their study underscores the urgent need for effective iron therapy in this demographic, as IDA is a leading cause of disability in women.

Downloaded from The Medical Journal of Clinical Nutrition and Family Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

(Resál et al., 2021) then delve into the specific challenges of managing IDA in patients with inflammatory bowel disease (IBD). They note that despite the prevalence of IDA in IBD patients, treatment is often overlooked, leading to diminished quality of life. Their advocacy for increased awareness and the preferential use of parenteral iron supplementation in these cases echoes the sentiments expressed by previous authors regarding the need for tailored treatment approaches.

(J. Malesza et al., 2022) contribute to the discourse by examining the intricate relationship between iron, inflammation, and gut microbiota. They highlight the dual challenges of treating IDA while considering the potential exacerbation of inflammatory conditions and gastrointestinal side effects associated with iron supplementation. Their findings advocate for personalized dietary recommendations alongside iron supplementation to optimize treatment outcomes.

(K Raut & M Hiwale, 2022) specifically address the implications of IDA in pregnancy, noting the scarcity of high-quality trials on the effects of iron therapy in this population. They report on the underutilization of IV iron despite emerging evidence supporting its safety and efficacy, particularly in pregnant women, thereby reinforcing the necessity for further research in this area.

The exploration of novel iron supplements is presented by (Jiang et al., 2022), who introduce a new chelate of pig skin collagen peptide and Fe(2+) as a promising treatment for IDA. Their findings suggest potential advancements in oral iron supplementation strategies, which could enhance treatment adherence and efficacy.

Lastly, (Rieg et al., 2023) examine the impact of IV iron formulations on the gut microbiome in a murine model. Their research indicates that while IV iron is essential for replenishing iron stores, it may also influence gut microbiota composition, raising important questions about the long-term implications of iron therapy on gut health.

Downloaded from The Medical Journal of Clinical Nutrition and Family Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

Overall, the literature reflects a growing understanding of IDA's complexities, the importance of tailored treatment strategies, and the need for continued research into the multifactorial aspects of iron metabolism and supplementation.

LITERATURE REVIEW

The article "Systemic Review and Clinical Management in Diagnosis and Treatment of the Iron Deficiency Anemia in Adults" by (FAHAD K ALSHARARI et al., 2017) provides a comprehensive overview of the complexities surrounding iron deficiency anemia (IDA), particularly focusing on its diagnosis and management. The authors emphasize the intricate mechanisms underlying iron metabolism, notably the role of hepcidin, which has been pivotal in elucidating how iron is regulated within the body. This insight is crucial for understanding the pathophysiology of IDA and highlights the need for targeted diagnostic approaches.

One of the significant contributions of this review is the introduction of the soluble transferrin receptor to ferritin ratio as a diagnostic tool for detecting iron deficiency. This metric enhances the ability to differentiate between true iron deficiency and anemia of chronic disease, which can often present similarly. The authors assert that a thorough exploration of the gastrointestinal tract is essential, given that most etiologies of iron deficiency stem from this area. They advocate for first-line investigations, such as upper gastrointestinal endoscopy and colonoscopy, to identify potential sources of blood loss or malabsorption. If these investigations yield negative results, further examination of the small bowel is warranted, underscoring the necessity of a systematic approach to diagnosis.

The article also delineates the criteria for diagnosing anemia, specifying hemoglobin thresholds that vary by sex and pregnancy status. This differentiation is vital for clinicians to accurately identify and manage IDA in diverse populations. Additionally, the authors highlight modern automated cell counters' capabilities in assessing red blood cell changes indicative of iron deficiency, such as reduced mean cell hemoglobin and increased hypochromic red cell percentage.

Downloaded from The Medical Journal of Clinical Nutrition and Family Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

These advancements in diagnostic technology facilitate more precise identification of IDA and improve the overall management of the condition.

In terms of treatment, the authors advocate for an aetiological approach whenever possible, emphasizing that iron supplementation—whether oral or parenteral—should be tailored to the underlying cause of the deficiency. This is particularly relevant for patients with renal failure or chronic inflammatory diseases, where functional iron deficiency may complicate treatment. The review effectively communicates the importance of addressing the root causes of IDA while also providing practical recommendations for iron supplementation.

The article "Treating iron deficiency in patients with gastrointestinal disease: Risk of re-attendance in secondary care" by (Tomkins et al., 2017) provides a comprehensive examination of iron deficiency (ID) and iron deficiency anemia (IDA) in the context of gastrointestinal (GI) diseases. The authors effectively highlight the prevalence of IDA among adult men and post-menopausal women in developed countries, and they emphasize the significant association between GI conditions—such as upper and lower gastrointestinal hemorrhage, peptic ulcers, and inflammatory bowel disease (IBD)—and the occurrence of ID and IDA.

One of the critical insights from the article is the relationship between IDA and healthcare utilization. The authors note that patients suffering from anemia are more likely to seek hospital care, which correlates with increased mortality rates. This aspect underscores the importance of effective management of IDA, as it not only affects patient health outcomes but also imposes additional costs on healthcare systems due to repeated hospital visits. The study suggests that the presence of concomitant GI diseases may exacerbate ID and IDA, influencing patient attendance in secondary care regardless of the primary diagnosis.

The article also addresses the therapeutic options available for treating ID, specifically focusing on oral and intravenous (IV) iron supplementation. The authors argue that IV iron is becoming increasingly favored due to its improved tolerance and efficacy, particularly in patients with GI disorders. This is a significant point, as the modern formulations of IV iron are associated with a

Downloaded from The Medical Journal of Clinical Nutrition and Family Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

lower risk of severe hypersensitivity reactions compared to older versions. Furthermore, the potential for more rapid iron replacement offered by IV formulations could be crucial for patients who may not respond adequately to oral iron due to malabsorption or other GI complications.

However, while the article presents a compelling case for the use of IV iron, it would benefit from a more detailed exploration of the comparative effectiveness of oral versus IV supplementation in various patient populations, particularly those with differing severities of GI disease. Additionally, a discussion on the long-term outcomes associated with each treatment modality could provide valuable insights into the most effective strategies for managing IDA in this demographic.

The article "Intravenous Irons: From Basic Science to Clinical Practice" by (Bhandari et al., 2018) provides a comprehensive examination of the management of iron deficiency anemia (IDA), emphasizing the limitations of oral iron therapy and the potential advantages of intravenous formulations. The authors highlight that while oral iron is a cost-effective and straightforward treatment option, its efficacy is often compromised by gastrointestinal side effects, which can deter patient adherence and lead to suboptimal management of IDA.

IDA is identified as the most prevalent nutritional deficiency globally, with significant implications for public health, particularly as it is frequently associated with various chronic conditions, including chronic kidney disease (CKD) and inflammatory bowel disease. The authors effectively argue that addressing IDA is crucial not only for improving individual patient outcomes but also for reducing overall healthcare burdens, such as transfusion rates and perioperative complications (Bhandari et al., 2018). The article underscores the importance of identifying the underlying causes of IDA, such as chronic blood loss from peptic ulcers or heavy menstrual bleeding, and malabsorption issues post-gastrectomy or due to chronic diseases.

Moreover, the authors present emerging evidence suggesting that treating non-anemic iron deficiency could also yield beneficial outcomes, expanding the scope

Downloaded from The Medical Journal of Clinical Nutrition and Family Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

of iron replacement therapy beyond traditional boundaries. This perspective is particularly relevant in Western countries, where the pathophysiology of IDA is often linked to chronic disease processes rather than dietary insufficiency.

The article "Iron Deficiency in Menstruating Adult Women: Much More than Anemia" by (Cristina Fernandez-Jimenez et al., 2020) provides a comprehensive examination of iron deficiency (ID) and its implications, particularly focusing on menstruating adult women. The authors highlight that ID is the most prevalent nutritional deficiency globally and serves as the primary cause of anemia across various demographics, with a notable emphasis on women of reproductive age and preschool children.

The article effectively outlines the progression of ID, starting from the depletion of tissue iron stores to impaired erythropoiesis, ultimately leading to anemia. This progression underscores the importance of early detection and intervention, as the authors argue that ID is not merely a hematological issue but a condition that can significantly affect various aspects of health. Notably, the study identifies a range of nonhematological manifestations associated with ID, including fatigue, reduced physical endurance, pica, restless legs syndrome (RLS), and cognitive impairments. These findings are critical, as they illuminate the broader health impacts of ID beyond anemia, which are often overlooked in clinical settings.

The article further emphasizes the detrimental effects of ID on women's health, particularly its potential to compromise maternal and neonatal outcomes. This aspect is crucial for healthcare providers, as it highlights the need for targeted screening and management strategies in women of reproductive age to mitigate risks associated with ID. The prospective analysis conducted by the authors on the characteristics and nonhematological signs of IDA, along with their response to iron therapy, adds valuable data to the existing literature.

The authors advocate for a more nuanced understanding of ID and its manifestations, calling for healthcare providers to consider both hematological and nonhematological symptoms in their assessments. This holistic approach is

Downloaded from The Medical Journal of Clinical Nutrition and Family Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

essential for effective management and treatment of IDA, as it can lead to improved health outcomes for affected individuals.

The article "Iron Deficiency Anemia in Inflammatory Bowel Disease: What Do We Know?" by (Resál et al., 2021) provides a comprehensive overview of the prevalence and management of iron deficiency anemia (IDA) in patients with inflammatory bowel disease (IBD). The authors emphasize that IDA is a frequent complication of IBD, particularly in developed countries, where it is often overlooked by healthcare providers. This neglect can significantly impact the disease's trajectory and adversely affect patients' quality of life (QoL).

The article critically examines the current understanding of IDA within the context of IBD, highlighting that while anemia is a common consequence of the disease, its treatment does not receive adequate attention from physicians. The authors argue that this oversight is concerning given the established correlation between anemia management and improved patient outcomes. They reference the European Crohn's and Colitis Organisation (ECCO) guidelines, which advocate for parenteral iron supplementation in specific cases of IDA associated with IBD. This recommendation underscores the necessity for healthcare professionals to prioritize iron supplementation as part of a holistic approach to managing IBD.

(Resál et al., 2021) further discuss the efficacy and safety of intravenous iron supplementation, citing international studies that suggest it is generally more effective than oral iron treatments for IBD patients. This assertion is particularly relevant given the challenges associated with oral iron, including gastrointestinal side effects and suboptimal absorption in patients with IBD. The authors call for increased awareness and utilization of both oral and intravenous iron treatments, suggesting that a more widespread implementation could lead to better management of IDA in this patient population.

Moreover, the article advocates for further research into third-generation iron agents, which may offer additional benefits in the treatment of IDA. The authors highlight the need for ongoing studies to explore the full potential of these newer therapies, as they could play a pivotal role in enhancing patient care.

Downloaded from The Medical Journal of Clinical Nutrition and Family Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

The article titled "The Dark Side of Iron: The Relationship between Iron, Inflammation and Gut Microbiota in Selected Diseases Associated with Iron Deficiency Anaemia—A Narrative Review" by (J. Malesza et al., 2022) presents a comprehensive examination of iron deficiency (ID) and iron deficiency anemia (IDA), highlighting their significance as global health issues. The authors emphasize that IDA predominantly impacts specific demographics, including premenopausal and pregnant women, children, and the elderly, while also acknowledging its association with lifestyle-related conditions such as obesity and chronic kidney disease.

A critical evaluation of the article reveals that the authors successfully delineate the dual objectives of IDA treatment: replenishing iron stores and normalizing hemoglobin concentrations. They advocate for a tailored approach to treatment, which includes a thorough assessment of the underlying causes of IDA and dietary iron intake. This individualized strategy is vital, as it allows for the identification of specific deficiencies and the implementation of targeted dietary modifications.

The article underscores the importance of dietary interventions, particularly the promotion of iron-rich foods, to combat IDA. The authors also recommend increasing vitamin C intake to enhance iron absorption while advising against the consumption of iron absorption inhibitors. This dietary focus is crucial as it aligns with contemporary nutritional strategies aimed at addressing IDA through non-pharmacological means.

Moreover, the article addresses the role of iron supplementation, both oral and parenteral, as a primary treatment modality. However, the authors provide a critical perspective on the potential side effects associated with iron supplementation, particularly concerning inflammation and gastrointestinal adverse events. This acknowledgment of adverse effects is essential for clinicians and patients alike, as it highlights the need for careful monitoring and consideration of individual patient responses to iron therapy.

Downloaded from The Medical Journal of Clinical Nutrition and Family Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

The article "Iron Deficiency Anemia in Pregnancy" by (K Raut & M Hiwale, 2022) provides a comprehensive overview of the challenges and considerations surrounding the management of iron deficiency anemia (IDA) in pregnant women. The authors highlight a significant gap in high-quality clinical trials that assess the maternal and neonatal outcomes of various iron therapies, specifically noting that only one prospective randomized trial comparing intravenous (IV) iron to oral iron met rigorous quality criteria. This lack of robust evidence underscores the need for further investigation into effective treatment options for IDA in pregnant populations.

The article discusses the historical context of IV iron therapy, which has been utilized due to its capacity for rapid iron replenishment. However, the authors emphasize the past concerns regarding the adverse effects associated with traditional iron formulations, particularly iron dextran. They report that approximately 25% of patients receiving iron dextran infusions experienced mild, self-limiting side effects, while more severe allergic or anaphylactic reactions have led to fatalities. This highlights a critical aspect of patient safety that must be considered when selecting iron supplementation methods during pregnancy.

Moreover, the authors note that despite the perceived safety of iron gluconate, its practical application is hindered by the necessity for multiple infusions, which may not be feasible in all clinical settings. This presents a challenge for healthcare providers who must balance the need for effective iron replenishment with the potential risks associated with different iron formulations.

The article also touches on the issue of blood transfusions in the management of IDA during pregnancy. The authors point out that the rationale for avoiding blood transfusions is not well understood, yet they found that neither treatment group in their referenced study required blood transfusions to address anemia. This observation raises important questions about the criteria used to manage severe cases of IDA and the implications of transfusion avoidance strategies.

The article titled "A new iron supplement: The chelate of pig skin collagen peptide and Fe(2+) can treat iron-deficiency anemia by modulating intestinal

Downloaded from The Medical Journal of Clinical Nutrition and Family Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

flora" authored by (Jiang et al., 2022) presents a novel approach to managing iron deficiency anemia (IDA) through the use of a chelated iron supplement. This research is particularly relevant given the global prevalence of IDA, which is recognized as one of the most common nutritional deficiencies.

The authors emphasize that oral iron supplementation remains the primary treatment for IDA. However, they highlight the limitations associated with traditional iron supplements, such as gastrointestinal side effects and poor absorption rates. In response to these challenges, the study investigates the efficacy of a new iron supplement that combines pig skin collagen peptides with ferrous iron (Fe(2+)). This innovative formulation is posited to enhance iron bioavailability and mitigate the adverse effects commonly associated with conventional iron supplements.

A critical evaluation of the article reveals several strengths. The authors provide a thorough background on the pathophysiology of IDA and the importance of gut health in iron metabolism. They present compelling evidence from their experimental studies, demonstrating that the chelated form of iron not only improves iron absorption but also positively influences the composition of intestinal flora. This dual action may contribute to better overall gut health, which is crucial for effective iron utilization.

Furthermore, the methodology employed in the study is robust, involving both in vitro and in vivo experiments that substantiate the proposed benefits of the new supplement. The results indicate a significant increase in hemoglobin levels and a reduction in inflammatory markers, suggesting that the chelate may offer a more effective treatment option for patients suffering from IDA.

However, while the findings are promising, the article does not extensively address potential long-term effects or the implications of altering intestinal flora. Future research should focus on the sustainability of these benefits and any possible repercussions of long-term use of the chelated iron supplement. Additionally, the study's sample size and demographic diversity could be expanded to enhance the generalizability of the results.

Downloaded from The Medical Journal of Clinical Nutrition and Family Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

The article titled "Intravenous ferric carboxymaltose and ferric derisomaltose alter the intestinal microbiome in female iron-deficient anemic mice" by (Rieg et al., 2023) presents a critical exploration of the effects of intravenous (IV) iron treatments on the gut microbiome in the context of iron deficiency anemia (IDA). The authors highlight the importance of iron not only as a necessary element for host physiology but also as a crucial nutrient for various bacterial species, which utilize iron through different mechanisms such as siderophore production and absorption of ferrous iron.

The article critically discusses the dual role of iron in promoting both host health and the proliferation of pathogenic bacteria, particularly in the context of iron supplementation. It notes that while oral iron is often the first line of treatment for IDA, it has been associated with adverse outcomes, including exacerbation of colitis in patients with inflammatory bowel disease and alterations in microbiota composition (Rieg et al., 2023). This raises significant concerns regarding the safety and efficacy of oral iron supplementation, particularly in vulnerable populations such as children, where it has been linked to increased virulence of enteric pathogens and subsequent gastrointestinal complications.

A key insight from the study is the bidirectional relationship between the gut microbiome and iron homeostasis. The authors explain that the microbiome can influence iron availability, suggesting that a healthy microbiome may be essential for optimal iron metabolism and absorption. This is particularly relevant given that the absence of a functional microbiome has been shown to result in anemia in experimental models. The findings indicate that while replenishing iron stores can restore some bacterial populations, it may also lead to the loss of certain iron-sensitive bacteria, thereby altering the overall microbiome composition (Rieg et al., 2023).

One of the significant contributions of this article is its focus on the effects of IV iron treatments, specifically ferric carboxymaltose and ferric derisomaltose, on the microbiome. The authors point out that despite the known impacts of dietary iron deficiency and oral iron supplementation on gut microbiota, the consequences of IV iron administration remain poorly understood. This gap in knowledge is

Downloaded from The Medical Journal of Clinical Nutrition and Family Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

crucial, as it suggests a need for further research to elucidate the microbiome's role in mediating the effects of different iron supplementation strategies.

CONCLUSION

The management of iron deficiency anemia (IDA) has evolved significantly, with recent literature emphasizing the complex interplay between iron metabolism, underlying health conditions, and treatment modalities. The comprehensive overview provided by (FAHAD K ALSHARARI et al., 2017) highlights the necessity of understanding hepcidin's role in iron regulation and the diagnostic tools available, such as the soluble transferrin receptor to ferritin ratio. This article underscores the importance of aetiological treatment approaches, advocating for tailored iron supplementation based on individual patient needs.

Building on this foundation, (Tomkins et al., 2017) explores the implications of gastrointestinal (GI) diseases on IDA management, suggesting that intravenous (IV) iron supplementation is often more effective for patients with compromised absorption. The limitations of oral iron therapy are further examined by (Bhandari et al., 2018), who note that while oral iron remains common, its gastrointestinal side effects can hinder treatment efficacy, particularly in patients with chronic conditions.

The literature also highlights the broader implications of ID in specific populations. For instance, (Cristina Fernandez-Jimenez et al., 2020) emphasizes the non-hematological manifestations of ID in menstruating women, which can significantly affect their quality of life. Furthermore, (Resál et al., 2021) address the challenges of managing IDA in patients with inflammatory bowel disease (IBD), advocating for increased awareness and the preferential use of parenteral iron supplementation in these cases.

The relationship between iron, inflammation, and gut microbiota is explored by (J. Malesza et al., 2022), who advocate for personalized dietary recommendations alongside iron supplementation to optimize treatment outcomes. The significance of IDA in pregnancy is highlighted by (K Raut & M Hiwale, 2022), who call for

Downloaded from The Medical Journal of Clinical Nutrition and Family Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

more research into the safety and efficacy of IV iron in this population, addressing the underutilization of effective treatment options.

Innovative approaches to iron supplementation are presented by (Jiang et al., 2022), who introduce a new chelated iron supplement that may enhance absorption and adherence. Lastly, (Rieg et al., 2023) examine the impact of IV iron on gut microbiota, raising important questions about the long-term implications of iron therapy on gut health.

In conclusion, the literature reflects a growing understanding of the multifaceted nature of IDA, emphasizing the importance of tailored treatment strategies that consider individual patient circumstances, underlying health conditions, and the potential implications of different iron supplementation methods. Continued research is essential to refine these approaches and enhance patient outcomes in the management of iron deficiency anemia.

DISCLOSURE STATEMENT

- Disclosure Statement : The authors have no conflicts of Interest to declare
- Funding Sources : None
- Acknowledgements : -
- Author Contribution : All authors discussed and contributed the final content for journal submission and publication

REFERENCES

1. FAHAD K ALSHARARI, M. A. J. E. D., Saleh S Alsharari, K., SHADEN BADER M, A. L. S. U. B. A. I. H., TAHER BO KHAMSEEN, A. H. M. E. D., SINAN BUKHAMSIN, B. E. S. M. A., Ayed O Almutairi, A., & Hasan Mubarak Alkathiry, A., 2017. Systemic Review and Clinical Management in Diagnosis and Treatment of the Iron Deficiency Anemia in Adults. [PDF]
2. Tomkins, S., Chapman, C., Myland, M., Tham, R., de Nobrega, R., Jackson, B., & Keshav, S., 2017. Treating iron deficiency in patients with gastrointestinal disease: Risk of re-attendance in secondary care. ncbi.nlm.nih.gov

Downloaded from The Medical Journal of Clinical Nutrition and Family Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

3. Bhandari, S., Pereira, D., Chappell, H. F., & Drakesmith, H., 2018. Intravenous Irons: From Basic Science to Clinical Practice. [PDF]
4. Cristina Fernandez-Jimenez, M., Moreno, G., Wright, I., Shih, P. C., Pilar Vaquero, M., & F. Remacha, A., 2020. Iron Deficiency in Menstruating Adult Women: Much More than Anemia. ncbi.nlm.nih.gov
5. Resál, T., Farkas, K., & Molnár, T., 2021. Iron Deficiency Anemia in Inflammatory Bowel Disease: What Do We Know?. ncbi.nlm.nih.gov
6. J. Malesza, I., Bartkowiak-Wieczorek, J., Winkler-Galicki, J., Nowicka, A., Dzięciołowska, D., Błaszczyk, M., Gajniak, P., Słowińska, K., Niepolski, L., Walkowiak, J., & Mądry, E., 2022. The Dark Side of Iron: The Relationship between Iron, Inflammation and Gut Microbiota in Selected Diseases Associated with Iron Deficiency Anaemia—A Narrative Review. ncbi.nlm.nih.gov
7. K Raut, A. & M Hiwale, K., 2022. Iron Deficiency Anemia in Pregnancy. ncbi.nlm.nih.gov
8. Jiang, S., Dong, W., Zhang, Z., Xu, J., Li, H., Zhang, J., Dai, L., & Wang, S., 2022. A new iron supplement: The chelate of pig skin collagen peptide and Fe(2+) can treat iron-deficiency anemia by modulating intestinal flora. ncbi.nlm.nih.gov
9. Rieg, T., Xue, J., Stevens, M., Thomas, L., White, J. R., & Dominguez Rieg, J. A., 2023. Intravenous ferric carboxymaltose and ferric derisomaltose alter the intestinal microbiome in female iron-deficient anemic mice. ncbi.nlm.nih.gov

Downloaded from The Medical Journal of Clinical Nutrition and Family Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved